Richard Siegler

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome
    R L Siegler
    Department of Pediatrics, Division of Nephrology and Hypertension, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    J Am Soc Nephrol 12:1458-67. 2001
  2. ncbi request reprint Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS)
    Richard L Siegler
    Division of Nephrology and Hypertension, Department of Pediatrics, University School of Medicine, 30 N 1900 E 2B422, Salt Lake City, UT 84132, USA
    Ren Fail 27:635-41. 2005
  3. ncbi request reprint Hemolytic uremic syndrome; pathogenesis, treatment, and outcome
    Richard Siegler
    Department of Pediatrics, Division of Nephrology, University of Utah School of Medicine, East Salt Lake City, Utah, USA
    Curr Opin Pediatr 17:200-4. 2005
  4. ncbi request reprint Clustering of post-diarrheal (Shiga toxin-mediated) hemolytic uremic syndrome in families
    R L Siegler
    Division of Nephrology and Hypertension, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, USA
    Clin Nephrol 60:74-9. 2003
  5. ncbi request reprint Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome
    Richard L Siegler
    Division of Pediatric Nephrology and Hypertension, Department of Pediatrics, 50 North 1900 East, 2B422, Salt Lake City, UT 84132 2204, USA
    Pediatr Nephrol 18:92-6. 2003
  6. ncbi request reprint Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome
    Richard L Siegler
    Pediatric Nephrology and Hypertension, Department of Pediatrics, University of Utah School of Medicine, 30 North 1900 East, 2B422, Salt Lake City, UT 84132 2204, USA
    Pediatr Nephrol 17:1053-8. 2002
  7. ncbi request reprint Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome
    Richard L Siegler
    Department of Pediatrics, Division of Nephrology and Hypertension, 30 N 1900 E, 28422, Salt Lake City, UT 84132 2204, USA
    Nephron 92:363-8. 2002
  8. ncbi request reprint Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome
    R L Siegler
    Department of Pediatrics, Division of Nephrology and Hypertension, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    Am J Nephrol 21:420-5. 2001
  9. doi request reprint Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome
    Robert S Oakes
    Division of Nephrology and Hypertension, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
    Pediatr Nephrol 23:1303-8. 2008
  10. ncbi request reprint Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome
    Frederic Clayton
    Department of Pathology, Salt Lake VA Medical Center, University of Utah School of Medicine, 50 N Medical Drive, Salt Lake City, 84132 2101, USA
    Am J Nephrol 25:536-40. 2005

Research Grants

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome
    R L Siegler
    Department of Pediatrics, Division of Nephrology and Hypertension, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    J Am Soc Nephrol 12:1458-67. 2001
    ..It is concluded that in the primate model, disease expression is modulated by the rate of Stx administration, and it is speculated that in the human, the rate of Stx absorption from the gut is one determinant of disease severity...
  2. ncbi request reprint Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS)
    Richard L Siegler
    Division of Nephrology and Hypertension, Department of Pediatrics, University School of Medicine, 30 N 1900 E 2B422, Salt Lake City, UT 84132, USA
    Ren Fail 27:635-41. 2005
    ..coli, little is known about factors that mediate the host response to these toxins and potentially contribute to pathogenesis. Nitric oxide (NO) is a candidate mediator by virtue of its antiplatelet and renal vasodilatory properties...
  3. ncbi request reprint Hemolytic uremic syndrome; pathogenesis, treatment, and outcome
    Richard Siegler
    Department of Pediatrics, Division of Nephrology, University of Utah School of Medicine, East Salt Lake City, Utah, USA
    Curr Opin Pediatr 17:200-4. 2005
    ..It is therefore relevant and appropriate that pediatricians remain familiar with the various subsets of the disease including its classification, management, and outcome...
  4. ncbi request reprint Clustering of post-diarrheal (Shiga toxin-mediated) hemolytic uremic syndrome in families
    R L Siegler
    Division of Nephrology and Hypertension, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, USA
    Clin Nephrol 60:74-9. 2003
    ..2. To compare familial with non-familial episodes, and concurrent familial with non-concurrent familial cases. 3. To determine the likelihood of Stx HUS occurring in a second family member...
  5. ncbi request reprint Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome
    Richard L Siegler
    Division of Pediatric Nephrology and Hypertension, Department of Pediatrics, 50 North 1900 East, 2B422, Salt Lake City, UT 84132 2204, USA
    Pediatr Nephrol 18:92-6. 2003
    ..coli is more likely to cause HUS than infection with organisms that produce only Stx1...
  6. ncbi request reprint Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome
    Richard L Siegler
    Pediatric Nephrology and Hypertension, Department of Pediatrics, University of Utah School of Medicine, 30 North 1900 East, 2B422, Salt Lake City, UT 84132 2204, USA
    Pediatr Nephrol 17:1053-8. 2002
    ..Our observations fail to support the use of heparin in preventing Stx-mediated HUS...
  7. ncbi request reprint Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome
    Richard L Siegler
    Department of Pediatrics, Division of Nephrology and Hypertension, 30 N 1900 E, 28422, Salt Lake City, UT 84132 2204, USA
    Nephron 92:363-8. 2002
    ..An inability to produce PGI(2) in response to endothelial cell injury could drive the pathogenic cascade. We therefore used a baboon model of HUS to measure PGI(2 )production following the administration of Stx and LPS...
  8. ncbi request reprint Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome
    R L Siegler
    Department of Pediatrics, Division of Nephrology and Hypertension, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    Am J Nephrol 21:420-5. 2001
    ..We speculate that LPS is not required for disease expression in the human, but that it can augment the response to otherwise subtoxic amounts of Stx and this augmentation may be mediated by LPS-induced cytokine release...
  9. doi request reprint Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome
    Robert S Oakes
    Division of Nephrology and Hypertension, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
    Pediatr Nephrol 23:1303-8. 2008
    ..2; 95% CI 5.1-240.5). These findings may help identify children who need periodic and extended follow-up after hospital discharge...
  10. ncbi request reprint Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome
    Frederic Clayton
    Department of Pathology, Salt Lake VA Medical Center, University of Utah School of Medicine, 50 N Medical Drive, Salt Lake City, 84132 2101, USA
    Am J Nephrol 25:536-40. 2005
    ..We used this model to test the hypothesis that LPS upregulates renal Stx receptor (Gb(3)) expression...
  11. ncbi request reprint Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy
    Sharon P Andreoli
    James Whitcomb Riley Hospital for Children, Well s Research Center, Room 2626, 702 Barnhill Drive, Indianapolis, IN 46223, USA
    Pediatr Nephrol 17:293-8. 2002
  12. ncbi request reprint Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome
    Richard L Siegler
    JAMA 290:1379-81. 2003
  13. ncbi request reprint von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome
    Theodore J Pysher
    Department of Pathology, Division of Pediatric Pathology, University of Utah, Primary Children s Medical Center, 100 N Medical Drive, Salt Lake City, UT 84113, USA
    Pediatr Dev Pathol 5:472-9. 2002
    ..The renal tissue findings, however, suggest a role for Stx-mediated intrarenal vWF release in the acute nephropathy of D+ HUS...
  14. ncbi request reprint NF-kappaB and neutrophils in post-diarrheal HUS
    Richard L Siegler
    Kidney Int 62:1088-90. 2002
  15. ncbi request reprint Predictors of fatality in postdiarrheal hemolytic uremic syndrome
    Robert S Oakes
    Pediatric Nephrology, University of Utah School of Medicine, Salt Lake City, Utah, USA
    Pediatrics 117:1656-62. 2006
    ..Describe the cause of deaths among patients with postdiarrheal hemolytic uremic syndrome (HUS) and identify predictors of death at the time of hospital admission...
  16. ncbi request reprint Prognostic significance of microalbuminuria in postdiarrheal hemolytic uremic syndrome
    Randall Lou-Meda
    Division of Nephrology and Hypertension, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, UT, USA
    Pediatr Nephrol 22:117-20. 2007
    ..7%, compared to screening for overt proteinuria alone. These findings, if confirmed by a larger cohort with more years of follow-up, may facilitate early initiation of intervention strategies designed to reduce progressive renal damage...
  17. ncbi request reprint Recurrent hemolytic uremic syndrome
    Richard L Siegler
    Clin Pediatr (Phila) 41:705-9. 2002
    ..We also present an HUS classification system that includes recurrence risk. It illustrates that recurrence is seen most frequently with familial HUS but can also occur in cases that are secondary to drugs, cancer, and pregnancy...

Research Grants1

  1. PATHOGENIC MECHANISMS AND INTERVENTION STRATEGIES IN HUS
    Richard Siegler; Fiscal Year: 2002
    ....